UPDATE 1-Qiagen beats estimates, tweaks outlook on test sales
* Sees FY adj EPS of $0.88-$0.90 vs $0.86-$0.90 previously
* Q3 adj net income $53.5 mln vs Rtrs poll avg of $49 mln
* Higher demand for tests for HPV, tumour mutations (Adds details, background)
FRANKFURT, Nov 9 (Reuters) - Germany's Qiagen QGEN.DE (QGEN.O: Cotización) tweaked its full-year earnings outlook and posted better-than-expected quarterly results as more doctors used its testing kits for the cervical cancer virus.
The genetic-tests specialist said on Monday that 2009 adjusted diluted earnings per share would be between $0.88 and $0.90, lifting the lower limit from $0.86 previously, adding that the target was based on Jan. 31 foreign exchange rates.
Healthcare reform in the United States, the group's biggest market, looked set to further boost demand for tests to identify the human papilloma virus (HPV), which can cause cervical cancer, Chief Executive Peer Schatz said.
"This would give us a bigger market potential. HPV tests are part of the standard healthcare coverage in the U.S.," the CEO told Reuters on Monday.
Qiagen -- listed in the Netherlands but with its main operations in Germany -- derives more than a quarter of total sales from genetic HPV tests.
Third-quarter net profit, excluding one-off items related to acquisitions, rose 26 percent to $53.5 million, better than the $49 million average estimate in a Reuters poll of 10 analysts. Continuación...